Zacks Investment Research upgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a sell rating to a hold rating in a research note issued to investors on Monday morning. The firm currently has $53.00 price target on the stock.

According to Zacks, “Fresenius Medical Care has had a disappointing run on the bourse on a year-to-date basis. The company  ended the second quarter on a mixed note wherein adjusted earnings missed the Zacks Consensus Estimate, while revenues beat the same. Fresenius Medical Care reiterated its full-year guidance. We believe this is in tune with the company’s long-term objective or the ‘Growth Strategy 2020’, wherein it aims to drive revenues to $28 billion by 2020, corresponding to an average annual growth rate of 10%. A wide range of dialysis products, initiatives to attain market traction, solid international foothold, strategic acquisitions and divestments are major catalysts. Fresenius Medical Care has signed an agreement to acquire NxStage Medical for $2 billion. However, a tough regulatory environment, difficulties in boosting the profit margin in foreign legal paradigms and competition in the niche markets are major headwinds.”

Several other research analysts have also recently weighed in on FMS. Nord/LB reiterated a buy rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. UBS AG reiterated a sell rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Royal Bank Of Canada reiterated a hold rating and issued a $44.00 price target on shares of Fresenius Medical Care Corporation in a report on Wednesday, July 5th. BidaskClub cut shares of Fresenius Medical Care Corporation from a strong-buy rating to a buy rating in a report on Monday, July 24th. Finally, DZ Bank AG reiterated a buy rating on shares of Fresenius Medical Care Corporation in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $48.33.

Shares of Fresenius Medical Care Corporation (FMS) opened at 47.99 on Monday. The firm has a 50-day moving average of $48.19 and a 200-day moving average of $46.76. The stock has a market cap of $29.45 billion, a P/E ratio of 20.60 and a beta of 0.48. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.53 by ($0.05). The firm had revenue of $4.47 billion for the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.96 EPS. On average, equities analysts expect that Fresenius Medical Care Corporation will post $2.35 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Fresenius Medical Care Corporation (FMS) Rating Increased to Hold at Zacks Investment Research” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/13/fresenius-medical-care-corporation-fms-rating-increased-to-hold-at-zacks-investment-research.html.

Several institutional investors have recently added to or reduced their stakes in the company. Harding Loevner LP boosted its holdings in shares of Fresenius Medical Care Corporation by 6.2% in the second quarter. Harding Loevner LP now owns 3,748,173 shares of the company’s stock valued at $181,149,000 after buying an additional 219,213 shares during the period. Cambiar Investors LLC boosted its holdings in shares of Fresenius Medical Care Corporation by 3.2% in the second quarter. Cambiar Investors LLC now owns 2,596,480 shares of the company’s stock valued at $125,488,000 after buying an additional 80,064 shares during the period. Bank of America Corp DE boosted its holdings in shares of Fresenius Medical Care Corporation by 12.1% in the first quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock valued at $62,917,000 after buying an additional 161,262 shares during the period. Royal Bank of Canada boosted its holdings in shares of Fresenius Medical Care Corporation by 6.4% in the second quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock valued at $24,248,000 after buying an additional 30,119 shares during the period. Finally, US Bancorp DE lifted its position in shares of Fresenius Medical Care Corporation by 10.4% in the second quarter. US Bancorp DE now owns 427,021 shares of the company’s stock worth $20,637,000 after purchasing an additional 40,121 shares in the last quarter. Institutional investors own 2.61% of the company’s stock.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.